Fake-carb entries with the MiniMed 780G in children and adolescents with type 1 diabetes
Official title: "Fake Carbs" Practice in the Glycemic Outcomes in Children and Adolescents Using AID System: A Cross-over Observational Study
Run by Athens General Children's Hospital "Pan. & Aglaia Kyriakou" · NCT07179471 · Data updated 2026-11-12
This test will see if entering 'fake' carbohydrate amounts into the MiniMed 780G changes blood sugar control in children and adolescents (ages 7–18) with type 1 diabetes who already use the device.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 7 Years to 19 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Athens General Children's Hospital "Pan. & Aglaia Kyriakou" Academic / other |
| Locations | 3 sites (Athens, Attica and 2 other locations) |
| Status | Recruiting |
| Started | June 4, 2025 |
| Main results expected | December 30, 2025 |
| Study ends | December 30, 2025 |
| Registry record updated | September 17, 2025 |
| Trial ID | NCT07179471 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children and adolescents aged 7–18 with type 1 diabetes who have been using the MiniMed 780G in automode for at least six months and who habitually enter fake carbohydrates.
✕Probably not a fit
Patients who do not use the MiniMed 780G, are outside the 7–18 age range, or have recent severe complications (recent DKA or severe hypoglycemia) are unlikely to benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This open-label, randomized crossover trial in Athens enrolls 40 children and adolescents (7–18 years) with type 1 diabetes who have been using the MiniMed 780G in automode for at least six months and habitually enter fake carbohydrates. Participants are randomized to a sequence of continuing versus stopping fake-carb entry, with each intervention phase lasting two weeks and separated by run-in and washout periods to allow algorithm adaptation. Continuous glucose outcomes (for example time-in-range and hyper/hypoglycemia metrics) during the fake-carb and no-fake-carb periods will be compared within each participant. The design aims to directly measure whether the common user behavior of entering fake carbs leads to meaningful changes in glucose control among pediatric users.
Why it matters
Potential benefit: If successful, the results could clarify whether fake-carb entry helps or harms glucose control and guide clearer self‑management advice for families using the MiniMed 780G.
How similar studies have gone: Previous clinical reports and analyses generally show that entering fake carbohydrates does not improve glycemic outcomes, and randomized pediatric crossover data on this behavior are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants aged 7-18 years * T1D \>6 months * on MiniMed 780G system in automode. Exclusion Criteria: * Participants with significant diabetes complications * Participants with severe episode of diabetic ketoacidosis in the last 6 months * Participants with hypoglycemia in the last 6 months.
Where it's running
-
Diabetes Center
Athens, Attica, Greece Recruiting -
Athens General Children's Hospital "Pan. & Aglaia Kyriakou"
Athens, Attica, Greece Active not recruiting -
Athens, Attiki
Athens, Attica, Greece Active not recruiting
Study contacts
- Study coordinator: Maria Chatzipsalti
- Email: endo1ped@aglaiakyriakou.gr
- Phone: +302132009855
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
VV-14300: a gene therapy approach for adults with type 1 diabetes not well controlled on an automated insulin system
This trial tests VV-14300 in adults with type 1 diabetes who aren’t reaching their blood sugar goals despite using an automated insulin delivery system.
-
New gene therapies VV-14299 and VV-14300 for adults with Type 1 Diabetes failing automated insulin delivery
This study tests VV-14299 and VV-14300, or VV-14300 alone, in adults with long-standing Type 1 Diabetes whose blood sugar remains poorly controlled despite using an automated insulin delivery system.
-
Oral verapamil in newly diagnosed children and teens with type 1 diabetes
This study tests whether taking verapamil by mouth can help preserve pancreatic beta cells and reduce insulin needs in kids and teens with recently diagnosed type 1 diabetes.
-
Preventing device-related skin rashes in kids with type 1 diabetes using hydrocolloid vs silicone patches
This study tests whether silicone-based or hydrocolloid patches help prevent recurring skin irritation from insulin pumps or CGMs in children and teens with type 1 diabetes.
-
AI-assisted remote insulin pump optimization for people with type 1 diabetes
This study tests an AI-powered tool that suggests insulin pump settings for people with type 1 diabetes, with doctor-approved recommendations delivered to a mobile app.
-
Near-sensor insulin delivery with CGM in people with type 1 diabetes
A small early-feasibility study tests a dual-port insulin patch pump that includes a CGM sensor to see if delivering insulin near the sensor affects glucose readings and whether an automated control algorithm can manage glucose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.